Cargando…

Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes

Cardiovascular risk reduction is an important issue in the management of patients with Type 2 diabetes mellitus. Peroxisome proliferator activated receptor (PPAR) agonists favourably influence glycaemic and lipid parameters in patients with Type 2 diabetes and a dual PPAR agonist is expected to have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatterjee, Sanjay, Majumder, Anirban, Ray, Subir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287720/ https://www.ncbi.nlm.nih.gov/pubmed/25573251 http://dx.doi.org/10.1038/srep07706

Ejemplares similares

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
por: Sosale, Aravind, et al.
Publicado: (2015)

An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Mitra, Asis
Publicado: (2020)

COVID-19 and Pre-existing Type 2 Diabetes Mellitus: A Retrospective Observational Study From Eastern India on the Association Between Glycaemic Control and Treatment Outcomes
por: Mukherjee, Poulomi, et al.
Publicado: (2023)

Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
por: Goyal, Omesh, et al.
Publicado: (2020)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
por: Shuja, Syed Hasan, et al.
Publicado: (2021)

Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience
por: Roy, Sayak
Publicado: (2020)

Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report
por: Roy, Sayak, et al.
Publicado: (2019)

Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach
por: Dabral, Swarna, et al.
Publicado: (2023)

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
por: Krishnappa, Manjunath, et al.
Publicado: (2020)

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
por: Jain, Mukul R, et al.
Publicado: (2015)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies
por: Chhabra, Manik, et al.
Publicado: (2022)

Glycaemic Effects of Non-statin Lipid-Lowering Therapies
por: Collins, Patrick D., et al.
Publicado: (2016)

Antidiabetic Effect of Tamarindus indica and Momordica charantia and Downregulation of TET-1 Gene Expression by Saroglitazar in Glucose Feed Adipocytes and Their Involvement in the Type 2 Diabetes-Associated Inflammation In Vitro
por: Saxena, Madhukar, et al.
Publicado: (2022)

Effect of Ramadan fasting on glycaemic parameters & body mass index in type II diabetic patients: A meta-analysis
por: Aydın, Neriman, et al.
Publicado: (2019)

Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control
por: Saligram, Shreyas, et al.
Publicado: (2012)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Lives of Gender Incongruent Community: An Indian Subset Chants “All is Well”
por: Majumder, Anirban, et al.
Publicado: (2020)

Identification of biomarkers for glycaemic deterioration in type 2 diabetes
por: Slieker, Roderick C., et al.
Publicado: (2023)

Excellent Outcome of Protocol-Based Treatment of Motivated Type 2 Diabetes Mellitus (T2DM) Patients: A Real World Follow-Up for 11 Years
por: Chatterjee, Sudip, et al.
Publicado: (2020)

Abstract 28: Change in glycaemic parameters in adults with type 2 diabetes initiated with or switched to insulin degludec/insulin aspart (IDegAsp) in a real-world setting – An analysis of Indian cohort of ARISE study
por: Baruah, Manash P, et al.
Publicado: (2022)

Carbohydrate profiling & glycaemic indices of selected traditional Indian foods
por: Shobana, Shanmugam, et al.
Publicado: (2022)

Poor Glycaemic Control Is Associated with Increased Lipid Peroxidation and Glutathione Peroxidase Activity in Type 2 Diabetes Patients
por: Gunawardena, Harshi Prasadini, et al.
Publicado: (2019)

Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Patel, Dhiren
Publicado: (2020)

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
por: Akbari, Rasoul, et al.
Publicado: (2021)

Effects of glycaemic management on diabetic kidney disease
por: MacIsaac, Richard J, et al.
Publicado: (2017)

Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
por: Dørflinger, Gry Høst, et al.
Publicado: (2017)

Adult‐onset type 1 diabetes: Predictors of glycaemic control
por: Hesse, Dan, et al.
Publicado: (2018)

The Effects of COVID-19 Lockdown on Glycaemic Control and Lipid Profile in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Ojo, Omorogieva, et al.
Publicado: (2022)

Effects of trunk extensor eccentric exercise on lipid profile and glycaemic response
por: Lee, Ho-Seong, et al.
Publicado: (2020)

Relationship between glycaemic control and lipid profile in type 2 diabetes mellitus patients in a low-resource setting
por: Nnakenyi, Ifeyinwa Dorothy, et al.
Publicado: (2022)

Effects of Ramadan Fasting on Glycaemic Control Among Patients with Type 2 Diabetes: Systematic Review and Meta-analysis of Observational Studies
por: Elmajnoun, Hala K., et al.
Publicado: (2023)

A Retrospective Observational Study of Insulin Glargine in Type 2 Diabetic Patients with Advanced Chronic Kidney Disease
por: Majumder, Anirban, et al.
Publicado: (2019)

Thyroid profile and autoantibodies in Type 1 diabetes subjects: A perspective from Eastern India
por: Sanyal, Debmalya, et al.
Publicado: (2017)

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
por: Vuppalanchi, Raj, et al.
Publicado: (2021)

The relation of low glycaemic index fruit consumption to glycaemic control and risk factors for coronary heart disease in type 2 diabetes
por: Jenkins, D. J. A., et al.
Publicado: (2010)

The effects of a structured education program on glycaemic control in individuals with type 1 diabetes
por: Pacheco, Ana Paula Franco, et al.
Publicado: (2015)

Exogenous ketosis in patients with type 2 diabetes: Safety, tolerability and effect on glycaemic control
por: Soto‐Mota, Adrian, et al.
Publicado: (2021)

EFFECT OF TAI CHI ON GLYCAEMIC CONTROL, LIPID METABOLISM AND BODY COMPOSITION IN ADULTS WITH TYPE 2 DIABETES: A META-ANALYSIS AND SYSTEMATIC REVIEW
por: GUO, Shuai, et al.
Publicado: (2021)

Liraglutide – Indian Experience
por: Anirban, Majumder, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8an960dbs6frggl07b1vn05rlg